(Q99956128)

English

Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult Volunteers (English)

0 references

1 reference

12 December 2021

https://clinicaltrials.gov/ct2/results?cond=&term=%22partial+thromboplastin+time%22

country

Russia

0 references

start time

11 September 2020

0 references

end time

30 November 2020

0 references

number of participants

500

0 references

clinical trial phase

phase III clinical trial

0 references

research subject recruitment status

recruiting

0 references

minimum age

18 year

0 references

maximum age

85 year

0 references

uses

partial thromboplastin time

1 reference

retrieved

12 December 2021

reference URL

https://clinicaltrials.gov/ct2/results?cond=&term=%22partial+thromboplastin+time%22

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT04540419

0 references

(Q99956128)

Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)